Research programme: anti-HIV therapy - BioLineRx

Drug Profile

Research programme: anti-HIV therapy - BioLineRx

Alternative Names: BL-1050

Latest Information Update: 07 Feb 2006

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Class
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 Jan 2006 Discontinued - Preclinical for HIV infections treatment in Israel (unspecified route)
  • 18 Jan 2005 Preclinical trials in HIV infections treatment in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top